{"generic":"C1 Esterase Inhibitor Recombinant","drugs":["C1 Esterase Inhibitor Recombinant","Ruconest"],"mono":{"0":{"id":"931008-s-0","title":"Generic Names","mono":"C1 Esterase Inhibitor Recombinant"},"1":{"id":"931008-s-1","title":"Dosing and Indications","sub":{"0":{"id":"931008-s-1-4","title":"Adult Dosing","mono":"<b>Hereditary angioedema, Acute attacks:<\/b> 50 international units\/kg IV (maximum 4200 international units\/dose); may repeat once if symptoms persist; max dose, 8400 international units\/24 hours "},"1":{"id":"931008-s-1-5","title":"Pediatric Dosing","mono":"<b>Hereditary angioedema, Acute attacks:<\/b> 13 years or older, 50 international units\/kg IV (maximum 4200 international units\/dose); may repeat once if symptoms persist; max dose, 8400 international units\/24 hours "},"3":{"id":"931008-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Hereditary angioedema, Acute attacks<br\/>"}}},"3":{"id":"931008-s-3","title":"Contraindications\/Warnings","sub":[{"id":"931008-s-3-9","title":"Contraindications","mono":"<ul><li>allergies to rabbits or rabbit-derived products<\/li><li>history of life-threatening immediate hypersensitivity reactions, including anaphylaxis, to C1 esterase inhibitor preparations<\/li><\/ul>"},{"id":"931008-s-3-10","title":"Precautions","mono":"<ul><li>Hematologic:<\/li><li>-- serious arterial and venous thromboembolic events have been reported in patients at risk; monitor patients with risk factors (eg, indwelling venous catheter or access device, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptives or certain androgens, morbid obesity, and immobility)<\/li><li>Immunologic:<\/li><li>-- severe hypersensitivity reactions (eg, hives, generalized urticaria, chest tightness, hypotension) may occur; discontinue<\/li><\/ul>"},{"id":"931008-s-3-11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"931008-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"931008-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Abdominal pain, Diarrhea (2%), Nausea (2%)<\/li><li><b>Neurologic:<\/b>Headache (up to 10%)<\/li><li><b>Respiratory:<\/b>Pain in throat<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Thromboembolic disorder<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Hypersensitivity reaction<\/li><li><b>Other:<\/b>Angioedema (up to 3%)<\/li><\/ul>"},"6":{"id":"931008-s-6","title":"Drug Name Info","sub":{"0":{"id":"931008-s-6-17","title":"US Trade Names","mono":"Ruconest<br\/>"},"2":{"id":"931008-s-6-19","title":"Class","mono":"Immune Modulator<br\/>"},"3":{"id":"931008-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"931008-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"931008-s-7","title":"Mechanism Of Action","mono":"C1 esterase inhibitor, a serine protease inhibitor, suppresses complement and contact pathway systems by irreversibly binding to and inactivating proteases such as kallikrein and factor XIIa. These actions on the contact pathway system prevent the formation of bradykinin, and regulate vascular permeability that is thought to contribute to hereditary angioedema attacks.<br\/>"},"8":{"id":"931008-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"931008-s-8-23","title":"Absorption","mono":"Tmax, IV: 0.31 hours <br\/>"},"1":{"id":"931008-s-8-24","title":"Distribution","mono":"Vd: 2.4 to 3 L <br\/>"},"3":{"id":"931008-s-8-26","title":"Excretion","mono":"Total body clearance: 781 to 1207 mL\/hr; nonlinear <br\/>"},"4":{"id":"931008-s-8-27","title":"Elimination Half Life","mono":"2.4 to 2.7 hours <br\/>"}}},"9":{"id":"931008-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>ensure vial is at room temperature; reconstitute with 14 mL sterile water for injection; mix by swirling slowly to avoid foaming<\/li><li>if dose requires more than 1 vial, may pool reconstituted vial contents together for administration<\/li><li>use reconstituted vials immediately or store for up to 8 hours at 2 to 8 degrees C (36 to 46 degrees F)<\/li><li>vials are for single-use only; discard partially used vials<\/li><li>administer via slow IV injection over 5 minutes, using a separate infusion line<\/li><li>initiate treatment under healthcare professional supervision; patients may be trained to self-administer<\/li><\/ul>"},"10":{"id":"931008-s-10","title":"Monitoring","mono":"<ul><li>resolution of signs and symptoms of hereditary angioedema is indicative of efficacy<\/li><li>thromboembolic signs and symptoms; in at-risk patients during and after use<\/li><\/ul>"},"11":{"id":"931008-s-11","title":"How Supplied","mono":"<b>Ruconest<\/b><br\/>Intravenous Powder for Solution: 2100 IU<br\/>"},"13":{"id":"931008-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to report symptoms of thromboembolism.<\/li><li>Side effects may include nausea, diarrhea, and headache.<\/li><li>Teach patient proper IV technique and placement if self-administered.<\/li><\/ul>"}}}